PCSA Processa Pharmaceuticals Inc
Price (delayed)
$0.3
Market cap
$1.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.87
Enterprise value
$462,954
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a
Highlights
The EPS has soared by 54% YoY and by 20% from the previous quarter
PCSA's debt has dropped by 51% year-on-year and by 24% since the previous quarter
Processa Pharmaceuticals's quick ratio has shrunk by 88% YoY and by 67% QoQ
Processa Pharmaceuticals's equity has shrunk by 66% YoY and by 54% QoQ
Key stats
What are the main financial stats of PCSA
Market
Valuations
Earnings
Shares outstanding
5.27M
Market cap
$1.58M
Enterprise value
$462,954
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.05M
Net income
-$11.85M
EBIT
-$11.85M
EBITDA
-$11.76M
Free cash flow
-$11.25M
Per share
Balance sheet
Liquidity
EPS
-$3.87
EPS diluted
-$3.87
Free cash flow per share
-$3.68
Book value per share
$0.52
Revenue per share
$0
TBVPS
$1.06
Total assets
$3.23M
Total liabilities
$1.53M
Debt
$73,507
Equity
$1.7M
Working capital
$340,988
Debt to equity
0.04
Current ratio
1.22
Quick ratio
0.78
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-184.3%
Return on equity
-233.2%
Return on invested capital
-2,099%
Return on capital employed
-698.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCSA stock price
How has the Processa Pharmaceuticals stock price performed over time
Intraday
-27.18%
1 week
-23.39%
1 month
-45.36%
1 year
-88.19%
YTD
-66.06%
QTD
-18.92%
Financial performance
How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.05M
Net income
-$11.85M
Gross margin
N/A
Net margin
N/A
PCSA's net income is down by 7% YoY and by 2.8% QoQ
Processa Pharmaceuticals's operating income has decreased by 5% YoY and by 3.6% QoQ
Growth
What is Processa Pharmaceuticals's growth rate over time
Valuation
What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 54% YoY and by 20% from the previous quarter
PCSA's P/B is 76% below its 5-year quarterly average of 3.3 and 34% below its last 4 quarters average of 1.2
Processa Pharmaceuticals's equity has shrunk by 66% YoY and by 54% QoQ
Efficiency
How efficient is Processa Pharmaceuticals business performance
Processa Pharmaceuticals's return on equity has shrunk by 65% YoY and by 19% QoQ
The ROA has plunged by 51% YoY and by 13% from the previous quarter
Processa Pharmaceuticals's return on invested capital has increased by 25% YoY
Dividends
What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCSA.
Financial health
How did Processa Pharmaceuticals financials performed over time
Processa Pharmaceuticals's total assets is 111% higher than its total liabilities
PCSA's total liabilities has surged by 92% year-on-year and by 26% since the previous quarter
Processa Pharmaceuticals's quick ratio has shrunk by 88% YoY and by 67% QoQ
PCSA's debt is 96% smaller than its equity
Processa Pharmaceuticals's equity has shrunk by 66% YoY and by 54% QoQ
PCSA's debt has dropped by 51% year-on-year and by 24% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.